SPARC (Support of Personalised Medicine Approaches in Cancer) is a three-year EU4Health project dedicated to transforming cancer care through personalised medicine across Europe.
Despite the proven potential of personalised medicine, access to diagnostics and treatments remains uneven across Member States. SPARC addresses these gaps by building a collaborative ecosystem where innovation meets implementation, ensuring every patient benefits from timely, data-driven, and equitable cancer care.
🧩 Project Coordination: A consortium of 17 partner organisations from 8 EU countries to advance equitable personalised cancer care across Europe.
🔍 What’s the Goal? SPARC will:
Through 7 pilot studies covering cancers such as lung, breast, pancreatic, melanoma, neuroblastoma, hematological, and adrenocortical tumours, SPARC will bridge science, policy, and clinical practice.
🗓️ Timeline: November 2025 – October 2028
🤝 Lungs Europe’s Vital Role: Lungs Europe leads Work Package 7 (WP7) on Patient, Citizens and Stakeholder Engagement. Our mission is to ensure patients public, carers, healthcare professionals and other stakeholders are meaningfully involved and their perspectives into SPARC’s design, implementation and outcomes. We are embedding patient and stakeholder perspectives into research and implementation, with a particular focus on patients and carers affected by cancers such as lung, breast, colorectal, prostate, melanoma, and rare forms of cancer.
